Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System – United States, September 1, 2022

Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System – United States, September 1, 2022 – March 31, 2023

Published:2024-04 Issue:9 Volume:42 Page:2380-2384
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Moro Pedro L.,Carlock Grace^ORCID,Fifadara Nimita,Habenicht Tei,Zhang Bicheng^ORCID,Strid Penelope^ORCID,Marquez Paige

Publisher

Elsevier BV

Reference25 articles.

1. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023

2. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine EUA LOA. https://www.fda.gov/media/150386/download Accessed July 6, 2023.

3. Food and Drug Administration. Moderna COVID-19 Vaccine EUA Letter of Authorization 04182023. https://www.fda.gov/media/144636/download Accessed July 6, 2023.

4. Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022. MMWR Morb Mortal Wkly Rep 2022;71:1436–1441. 10.15585/mmwr.mm7145a2.

5. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 in Pregnancy: An Update for Clinicians;Clinical Obstetrics & Gynecology;2024-07-05